Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 Full Year 2023 Earnings Conference Call February 27, 2024 8:30 AM ET
Company Participants
Cedric Francois - Co-Founder and Chief Executive Officer
Tim Sullivan - Chief Financial Officer
Adam Townsend - Chief Operating Officer
Caroline Baumal - Chief Medical Officer
Meredith Kaya - SVP of Investor Relations and Strategic Finance
Conference Call Participants
Jonathan Miller - Evercore
Tazeen Ahmad - Bank of America
Anupam Rama - J.P. Morgan
Yigal Nochomovitz - Citigroup
Steven Seedhouse - Raymond James
Colleen Kusy - Baird
Phil Nadeau - TD Cowen
Eliana Merle - UBS
Joseph Stringer - Needham & Company
Derek Archila - Wells Fargo
Douglas Tsao - H.C. Wainwright
Graig Suvannavejh - Mizuho
Operator
Good morning ladies and gentlemen. Thank you for standing by and welcome to the Apellis Pharmaceuticals Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised, today’s conference is being recorded.
I will now hand the conference over to your speaker host, Meredith Kaya, Senior Vice President of Investor Relations and Strategic Finance. Please go ahead.
Meredith Kaya
Good morning and thank you for joining us to discuss Apellis' fourth quarter and full year 2023 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Operating Officer, Adam Townsend; Chief Medical Officer, Dr. Caroline Baumal; and Chief Financial Officer, Tim Sullivan.
Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.
Now, I’ll turn the call over to Cedric.
Cedric Francois
Thank you, Meredith, and thank you all for joining us this morning. As I reflect on this past year, I am extremely proud of our team and all of our achievements in 2023. Our two commercial products, SYFOVRE and EMPAVELI, are making meaningful differences for patients.
The year ended with SYFOVRE in a very strong position, and we remain encouraged by the continued uptake and high compliance rates for EMPAVELI in PNH. We also had multiple positive data readouts, including up to three years of efficacy and safety data from both of our approved therapies.